Endocrine Abstracts

Introduction: Recent studies defend the measurements of insulin resistance and β-cell function to assess the endocrine pancreatic function in patients with cystic fibrosis (CF). HOMA-IR indexes greater than 1 translate insulin resistance and HOMA-%β values lower than 100% imply an altered β-cell function.

Aim: To describe insulin resistance and β-cell function using HOMA-IR and HOMA-%β indexes in patients with CF and compare them according to their glucose tolerance.

Methods: Observational, cross-sectional, clinical research on patients with CF evaluated at Hospital Universitario Reina Sofía (Córdoba). Statistical analysis performed with SPSS software.

Results: 31 patients were included in our study. The mean age was 32.25±8.89 years, with a mean CF evolution time of 23.45±10.21 years. 61.3% of the patients were women. After the oral 75g-glucose test (OGTT) 13.8% patients were diagnosed with cystic-fibrosis related diabetes (CFRD), 25.1% with impaired glucose tolerance (IGT) and 51.7% showed a normal glucose tolerance. 50% of patients with IGT or CFRD had an HOMA-IR > 1 compared to the 18.2% of patients with normal tolerance who had an index greater than 1. The difference was not statistically significant (P=0.208). 57.1% of patients with IGT or CFRD had an HOMA-%b < 100% in comparison to the 36.4% of patients with normal glucose tolerance who had an HOMA-%b < 100% (P=0.302).

Conclusions: – In our series, half of the patients with IGT or CFRD showed abnormal insulin resistance indexes but there are not statistically significant differences with the indexes of those patients with normal glucose tolerance.

– Most of the patients (57.1%) with CF and abnormal glucose tolerance in our study presented with an impaired β-pancreatic cell function. This proportion is smaller in patient with normal glucose tolerance (36.4%) but the difference was not statistically significative.

Keywords: Diabetes, cystic fibrosis, complications.